Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease.
Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease.
复制标题
依替巴肽对镰状细胞病急性疼痛发作期间炎症的影响。
DOI：
10.1002/ajh.25032
复制
发表时间：
2018
影响因子：
12.8
通讯作者：
Ataga,KennethI
中科院分区：
文献类型：
--
作者：
Brittain,JuliaE;Anea,Ciprian;Desai,Payal;Delaney,Jack;McDonald,Adam;Looney,StephenW;Key,NigelS;Parise,LeslieV;Ataga,KennethI
The contribution of platelets to sickle cell disease (SCD) pathophysiology remains incompletely defined. Platelet activation is increased during acute pain episodes, coincident with increased inflammation, endothelial activation and platelet-leukocyte interaction. We conducted a single-center, phase II, double-blind, placebo-controlled study to evaluate the safety of eptifibatide, a glycoprotein IIb/IIIa inhibitor, in combination with “standard of care,” for the treatment of patients during an acute pain episode. Details of the study design, randomization schema and primary outcomes of the study have been previously reported1. Here, we perform a secondary analysis of the effect of eptifibatide on ex vivo platelet function, platelet-leukocyte aggregates, coagulation activation, endothelial activation and inflammatory markers in patients during the study.Details of the Methods are provided in the Supplementary Data. Results are provided for 6 eptifibatide treated and 3 placebo patients for whom complete data are available. Baseline demographic and laboratory data are shown in Supplementary Table 1. Eptifibatide significantly reduced plasma levels of platelet α-granule specific proteins, CD40L
